Vitruvias 30mg Thyroid Tablets Recalled — Now the FDA’s Highest Risk Level

If you or a family member takes Vitruvias Therapeutics’ Thyroid Tablets, USP 30 mg, check your bottle now. One lot may be stronger than labeled, and on September 22, 2026, the FDA classified this recall as Class I — its most serious risk category, meaning use of the product could reasonably cause serious health consequences or death. Don’t stop taking it without talking to your healthcare provider first.

Quick Facts

Field	Detail
Product	Vitruvias Therapeutics Thyroid Tablets, USP 30 mg
NDC	69680-166-00
Lot Number	504950
Expiration Date	September 30, 2026
Reason for Recall	Potential for the product to be superpotent (stronger than labeled)
FDA Risk Classification	Class I — the FDA’s highest risk level, as of September 22, 2026
Distribution	Nationwide, to Vitruvias’ direct accounts, January 31, 2025 to September 30, 2025
Units Released / Sold	3,655 released; 1,955 sold
Adverse Events Reported	None, as of the recall notice’s publication
Original Recall Announced	August 21, 2026 (company); published by FDA August 24, 2026
Company Contact	Roger Graben, (256) 239-9373, [email protected], Monday–Friday, 9 a.m.–5 p.m. CT

Is This About Your Medication?

Check your bottle for lot number 504950 and NDC 69680-166-00. The tablets are off-white to pale brown, round, and may display small flecks. One side is debossed “THY,” the other “050.” If your bottle doesn’t match this lot number, this specific recall doesn’t apply to you — but if you take this drug and aren’t sure which lot you have, check with your pharmacy.

Why “Superpotent” Thyroid Medication Is Dangerous

This medication, Thyroid, USP, is a natural preparation made from porcine thyroid glands, containing both levothyroxine and liothyronine. It’s used to treat hypothyroidism — an underactive thyroid. If a tablet actually contains more hormone than its label says, taking it can push you into hyperthyroidism instead: an overactive thyroid.

The symptoms can include weight loss, heat intolerance, fatigue, nervousness, muscle weakness, high blood pressure, chest pain, a rapid heart rate, or heart rhythm disturbances. Three groups face the highest risk, especially with extended exposure: the elderly, who face a higher risk of cardiac complications from excess thyroid hormone; pregnant women, where overtreatment is linked to premature delivery and low birth weight; and infants, where overtreatment can affect growth and development.

That’s the reason this recall moved from a routine notice to the FDA’s top risk category — not a one-time side effect, but a medication doing the opposite of what it’s supposed to, for as long as you keep taking it.

Do Not Just Stop Taking This Medication

This is the single most important thing to know: if you’re currently taking tablets from Lot 504950, don’t stop cold. Thyroid hormone levels need to be managed carefully, and abruptly discontinuing thyroid medication carries its own risks. Contact your healthcare provider for guidance and, if needed, a replacement prescription — they may want to check your levels or transition you to a different product rather than leave you without treatment.

What Changed: Voluntary Recall to Class I

Vitruvias Therapeutics announced this as a voluntary recall on August 21, 2026, after its own testing confirmed the potential for superpotency, and the FDA published that notice on August 24, 2026. At that point, the company said it wasn’t aware of any adverse events tied to the affected lot.

More than four weeks later, on September 22, 2026, the FDA reclassified the recall as Class I. That upgrade reflects the FDA’s judgment about the potential severity of harm from continued exposure — it doesn’t necessarily mean new injuries have been confirmed, but it does mean the agency now treats this as carrying a reasonable probability of serious health consequences or death if the affected product is used.

A Note on Reaching the Company

Some reporting on this recall’s Class I reclassification has referenced the manufacturer having ceased operations. This article could not independently confirm that from the FDA’s own recall notice or the company’s official contact information, which still lists an active consumer contact. If you call or email Vitruvias and don’t get a response, don’t wait — go directly to your pharmacist or prescribing physician, who can help you get a replacement prescription regardless of whether the manufacturer is reachable.

What You Should Do

1. Check your bottle for lot number 504950 and NDC 69680-166-00.
2. If it matches, do not stop taking it — contact your healthcare provider first for guidance and a possible replacement prescription.
3. Contact Vitruvias Therapeutics at (256) 239-9373 or [email protected] with questions about the recall itself.
4. If you or a family member has experienced symptoms of an overactive thyroid — rapid heartbeat, unexplained weight loss, heat intolerance, chest pain — while taking this lot, tell your provider and consider reporting it to the FDA.
5. Report any adverse reaction or quality problem to the FDA’s MedWatch program, online or by calling 1-800-332-1088 for a paper form.

Why Is an “Unapproved” Thyroid Drug Legally on the Market?

You may see references to this product’s labeling stating it hasn’t been approved by the FDA as a new drug. That’s not unique to Vitruvias — desiccated thyroid extract products like this one have historically been marketed under a different, older regulatory framework than synthetic levothyroxine, predating the FDA’s modern new-drug approval process for this drug class. That history doesn’t change the seriousness of a confirmed superpotency finding, but it explains a detail that can otherwise look alarming out of context.

Frequently Asked Questions

Should I stop taking my thyroid medication right now?

 No — not without talking to your healthcare provider first. Stopping thyroid medication abruptly carries its own health risks. Contact your provider for guidance and, if appropriate, a replacement prescription.

Has anyone been harmed by this specific lot?

 As of the recall notice’s publication, Vitruvias Therapeutics said it had not received any reports of adverse events related to this recall. The Class I classification reflects the FDA’s assessment of potential risk, not confirmed injuries.

What does “Class I” actually mean? 

It’s the FDA’s highest recall risk category, meaning the agency has determined that using the product could reasonably be expected to cause serious adverse health consequences or death.

How do I know if my specific bottle is affected?

 Check for lot number 504950 and NDC 69680-166-00 on your bottle’s label. Only this specific lot is included in this recall.

What if I can’t reach Vitruvias Therapeutics? 

Contact your pharmacist or prescribing physician directly — they can help you get a replacement regardless of whether you’re able to reach the manufacturer.

Could I have a legal claim if I or a family member was harmed by this medication?

 Possibly, particularly if you experienced documented symptoms of hyperthyroidism while taking tablets from this lot. A products liability or pharmaceutical injury attorney can evaluate whether your specific medical history and this recall support a claim.

Sources Used in This Article

• U.S. Food and Drug Administration — “Vitruvias Therapeutics, Inc Issues Nationwide Recall of One Lot of Thyroid Tablets, USP 30 mg Due to Potential Super Potency,” published August 24, 2026: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/vitruvias-therapeutics-inc-issues-nationwide-recall-one-lot-thyroid-tablets-usp-30-mg-due-potential
• Qz — “The FDA on Sept. 22 classified the recall of one lot of Vitruvias Therapeutics’ 30 mg thyroid tablets as Class I,” updated September 24, 2026: https://qz.com/vitruvias-therapeutics-thyroid-tablet-recall-fda-class-i-092426

Researched and written by Israr Ahmad, legal content researcher and founder of AllAboutLawyer.com. All facts verified against the official FDA recall notice and reporting on its Class I reclassification on September 26, 2026. Last Updated: September 26, 2026.

This article is for informational purposes only and does not constitute legal or medical advice. Laws vary by state and individual circumstances differ. For advice about your specific situation, consult a qualified attorney or physician. This is a sensitive health topic — if you have concerns about a medication you or a loved one is taking, please contact your healthcare provider directly.